Mirum Pharmaceuticals (MIRM) Change in Receivables (2022 - 2026)

Mirum Pharmaceuticals' Change in Receivables history runs 5 years deep, the most recent figure standing at $12.9 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 23.45% year-over-year to $12.9 million; the TTM figure through Mar 2026 stood at $44.1 million (up 6.99% YoY), while the FY2025 annual figure was $48.1 million, up 320.58% from the prior year.
• Change in Receivables was $12.9 million for Q1 2026 at Mirum Pharmaceuticals, down from $19.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $20.1 million in Q4 2023 to a low of -$13.0 million in Q1 2024.
• Historically, Change in Receivables has averaged $8.1 million across 5 years, with a median of $8.1 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Change in Receivables jumped 432.94% in 2023, then plunged 2044.38% in 2024.
• A 5-year view of Change in Receivables shows it stood at $7.7 million in 2022, then soared by 162.95% to $20.1 million in 2023, then sank by 46.04% to $10.9 million in 2024, then surged by 74.96% to $19.0 million in 2025, then plunged by 32.21% to $12.9 million in 2026.
• The last three Change in Receivables figures came in at $12.9 million (Q1 2026), $19.0 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.